Cytogen/Matritech BladderChek
This article was originally published in The Gray Sheet
Executive Summary
Restructured marketing agreement calls for Cytogen to target oncologists while Matritech focuses on urologists. The point-of-care, urine-based bladder cancer screening test was 510(k)-cleared last July (1"The Gray Sheet" May 5, 2003, p. 25)...
You may also be interested in...
Matritech Will Stress BladderChek Rapid Screen Accuracy As Selling Point
Matritech will highlight the BladderChek point-of-care bladder cancer screening test's sensitivity, about twice that of standard cytology evaluations, to promote the technology among urologists
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.